Genoptix, Inc. will provide expertise in flow cytometry testing to Biogen Idec and will collaborate with the company in assay development to support upcoming clinical trials.

Genoptix provides personalized clinical esoteric services to hematologists/oncologists, which aid in the evaluation and management of hematomalignancies. The company also supports clinical trails in the hematomalignancy area.

“This opportunity allows both Genoptix and Biogen Idec to work to their respective strengths and improve the development of new drugs,” said Tina Nova, Ph.D., Genoptix president and chief executive officer. “We feel strongly that our organization is well poised to provide the type of flexibility, innovative thinking and collaborative approach that will help create value for both companies and benefit physicians and patients. Our medical and laboratory team has tremendous experience across varied laboratory platforms, whether that is 6 color flow, quantitative PCR or cellular assays, but the main focus is always on quality and integration of services.”